Filters








154,475 Hits in 3.4 sec

Modelling vaccination schedules for a cancer immunoprevention vaccine

Santo Motta, Filippo Castiglione, Pierluigi Lollini, Francesco Pappalardo
2005 Immunome Research  
Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine.  ...  This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma.  ...  Conclusion We presented an in silico search for effective cancer vaccination protocols using a model describing the action of a tumor vaccine in stimulating immune response and the ensuing competition  ... 
doi:10.1186/1745-7580-1-5 pmid:16305756 pmcid:PMC1287065 fatcat:5d4tzh7p3zap3jj6vgd2fiypi4

Business models and opportunities for cancer vaccine developers

Alex Kudrin
2012 Human Vaccines & Immunotherapeutics  
Lessons learned from some developing countries and especially from South Korea illustrate that further growth of cancer vaccine industry will depends not only on new business models but also will heavily  ...  D espite of growing oncology pipeline, cancer vaccines contribute only to a minor share of total oncology-attributed revenues.  ...  Dependently on individual portfolio and business strategy circumstances, cancer vaccine developers may opt for different business model.  ... 
doi:10.4161/hv.20629 pmid:22894953 pmcid:PMC3660762 fatcat:2hzyw5qe7jetdjdmkcor66v4ye

Modeling and simulation of cancer immunoprevention vaccine

F. Pappalardo, P.-L. Lollini, F. Castiglione, S. Motta
2005 Bioinformatics  
Our in silico model was able to closely reproduce the effects of various vaccination protocols.  ...  We present an in silico model that simulates the immune system responses to tumor cells in naive and vaccinated mice.  ...  The most thoroughly investigated model of cancer immunoprevention is the mammary carcinoma of HER-2/neu transgenic mouse.  ... 
doi:10.1093/bioinformatics/bti426 pmid:15817697 fatcat:gqae7xn7cza6vfgr6gdqvcnuf4

Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer

Nathalie Machluf, Ruth Arnon
2012 World Journal of Vaccines  
Flagella-based MUC1 vaccines were tested in therapeutic setting in two aggressive breast cancer models, comprising the implantation of the 4T1-MUC1 cell line in either Balb/c, or Human MUC1 transgenic  ...  MUC1, a tumor-associated antigen overexpressed in many carcinomas, represents a candidate of choice for cancer immunotherapy.  ...  Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer  ... 
doi:10.4236/wjv.2012.23015 fatcat:3ahhhr254rgiza3alav55trz3u

Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era

T. Malagon, M. Drolet, M.-C. Boily, J.-F. Laprise, M. Brisson
2014 Cancer Epidemiology, Biomarkers and Prevention  
Inequalities in cervical cancer may be increased following mass vaccination against the human papillomavirus (HPV) if girls with low vaccine uptake also have low future participation in cervical cancer  ...  We modeled the impact of vaccination on SCC incidence rate differences (absolute inequality) and incidence rate ratios (relative inequality) between women who have routine screening intervals of <5 years  ...  The impact of herd effects is measured by the difference in predicted vaccine impact between our base model and the modified counterfactual model without herd effects. Inequality measures.  ... 
doi:10.1158/1055-9965.epi-14-1052 pmid:25380735 fatcat:kggchja54nblvee4fxorfnu3he

The Cancer Vaccine Collaborative: a new model of coordinated discovery

Jill O'Donnell-Tormey, Edward A McDermott
2012 Cancer Immunity  
CRI, on the other hand, had been supporting clinical research utilizing the typical academic model of a call for papers followed by peer review, but this model was not generating the impact the Institute  ...  Looking back, we realize how little was truly known about the human immune response to cancer antigens and to cancer vaccination.  ... 
pmid:22896755 pmcid:PMC3380350 fatcat:owgd6snsbbbczmkyyocvsdc62i

Animal models of tumor immunity, immunotherapy and cancer vaccines

Suzanne Ostrand-Rosenberg
2004 Current Opinion in Immunology  
Transgenic mouse models in which tumors arise spontaneously have been developed for most cancers.  ...  Although animal models are becoming more sophisticated, additional improvements are needed so that more realistic models can be developed.  ...  Models for testing immunotherapy and cancer vaccines In developing better animal models for both immunotherapy and cancer vaccine studies, investigators have tried to address the problems associated with  ... 
doi:10.1016/j.coi.2004.01.003 pmid:15023405 fatcat:e7rpwzqxtjgxlkdwxw2am2aovq

Modeling flow cytometry data for cancer vaccine immune monitoring

Jacob Frelinger, Janet Ottinger, Cécile Gouttefangeas, Cliburn Chan
2010 Cancer Immunology and Immunotherapy  
Results from model-based analysis will be illustrated with examples from FCM assays commonly used in cancer immunotherapy laboratories.  ...  Flow cytometry (FCM) is widely used in cancer research for diagnosis, detection of minimal residual disease, as well as immune monitoring and profiling following immunotherapy.  ...  (CIC) ImmunoAssay Working Group (IAWG), Cancer Immunotherapy Association (CIMT) Cancer Immunoguiding Program (CIP) and NIAID/BD ICS Quality Assurance Program (QAP) steering committees.  ... 
doi:10.1007/s00262-010-0883-4 pmid:20563720 pmcid:PMC2892609 fatcat:cbrzutk5lna5ljn3h4qjwdan6q

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

Geoffrey P. Garnett, Jane J. Kim, Katherine French, Sue J. Goldie
2006 Vaccine  
To date, model results are consistent in predicting a useful role for vaccine, but further epidemiological data are required to help test the validity of models.  ...  The impact of human papillomavirus (HPV)-16/18 vaccination on the incidence of infection and disease can be explored in a range of different models.  ...  Sue Goldie gratefully acknowledges the support of the US National Cancer Institute (grant #R01 CA093435) and The Bill and Melinda Gates Foundation (grant #30505).  ... 
doi:10.1016/j.vaccine.2006.05.116 pmid:16950005 fatcat:qkg7siix4rcz5deyx2jdnxqjw4

Modeling Cervical Cancer Prevention in Developed Countries

Jane J. Kim, Marc Brisson, W. John Edmunds, Sue J. Goldie
2008 Vaccine  
This article is a focused review on existing mathematical models that have been used to evaluate HPV vaccination in the context of developed countries with existing screening programs.  ...  Despite variations in model assumptions and uncertainty in existing data, pre-adolescent vaccination of girls is consistently found to be attractive in the context of current screening practices, provided  ...  Goldie are also funded in part by the Bill and Melinda Gates Foundation (30505) for modeling of HPV and cervical cancer in developing countries.  ... 
doi:10.1016/j.vaccine.2008.06.009 pmid:18847560 pmcid:PMC2769256 fatcat:dwiwqg2lsfc5flfjvmdpcdujv4

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human

Cheryl Lai-Lai Chiang, Raphaël Rovelli, Apostolos Sarivalasis, Lana E. Kandalaft
2021 Cancers  
Other emerging models, including patient-derived xenograft and genetically engineered mouse models, are continuing to improve and can be useful for evaluating cancer vaccination therapies in the near future  ...  Using the murine ID8 ovarian tumor model, we provide evidence that a cancer vaccine can be effectively combined with OC standard-of-care to achieve greater overall efficacy.  ...  We have used the ID8 tumor model extensively for evaluating cancer vaccination strategies.  ... 
doi:10.3390/cancers13184553 pmid:34572778 fatcat:wkfjeoou2ffkhj3at4m4ssdawu

Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model

Xiulan Lai, Avner Friedman, Nikolas K. Haass
2017 PLoS ONE  
In this paper we consider a combination therapy of cancer. One drug is a vaccine which activates dendritic cells so that they induce more T cells to infiltrate the tumor.  ...  The variables include dendritic and cancer cells, CD4 + and CD8 + T cells, IL-12 and IL-2, GM-CSF produced by the vaccine, and a T cell checkpoint inhibitor associated with PD-1.  ...  a1111111111 a mathematical model which combines a cancer vaccine with a checkpoint inhibitor: the vaccine (GVAX) increases the pool of T cells and the checkpoint inhibitor (anti-PD-1) enables the T cells  ... 
doi:10.1371/journal.pone.0178479 pmid:28542574 pmcid:PMC5444846 fatcat:bcaocs5z5fftdjjt3kxsnecqiq

Finding a role for cancer vaccines in pancreatic cancer: a model of resilience

Gentry King, Steven Green, E. Gabriela Chiorean
2021 Hepatobiliary surgery and nutrition  
Along with IMPRESS, and the multitude of other negative vaccine studies, results from PILLAR underscore the complexities of translating cancer vaccines into successful treatments for PDA.  ...  Single-agent or combination immuno-, chemo-, and radio-immunotherapies, including anti-PD1, anti-CTLA 4, oncolytic viruses, cancer vaccines, and T cells adoptive immunotherapies have been unsuccessful  ... 
doi:10.21037/hbsn-2021-26 pmid:35284521 pmcid:PMC8847880 fatcat:3ejh6ow36bbxxkksd5ewbpxl6m

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model

Yi-Ru Pan, Chiao-En Wu, Ming-Huang Chen, Wen-Kuan Huang, Hsuan-Jen Shih, Keng-Li Lan, Chun-Nan Yeh
2020 Vaccines  
We used a thioacetamide (TAA)-induced intrahepatic cholangiocarcinoma (iCCA) rat model to investigate the DNA vaccine potential against CTLA4, PD-1, and PD-L1.  ...  In our TAA-induced iCCA rat model, the expression of PD-L1 and the infiltration of CD8+ T cells increased as in rat CCA tumorigenesis.  ...  vaccine from the rat iCCA model.  ... 
doi:10.3390/vaccines8040703 pmid:33255375 pmcid:PMC7712087 fatcat:ani3eeqisfgjtfyquzornsj2si

On immunotherapies and cancer vaccination protocols: A mathematical modelling approach

Badal Joshi, Xueying Wang, Sayanti Banerjee, Haiyan Tian, Anastasios Matzavinos, Mark A.J. Chaplain
2009 Journal of Theoretical Biology  
In this paper we develop a new mathematical model of immunotherapy and cancer vaccination, focusing on the role of antigen presentation and costimulatory signaling pathways in cancer immunology.  ...  We investigate the effect of different cancer vaccination protocols on the well-documented phenomena of cancer dormancy and recurrence, and we provide a possible explanation of why adoptive immunotherapy  ...  We investigate the effect of different cancer vaccination protocols on the well-documented phenomena of cancer dormancy and recurrence, and we provide a possible explanation of why adoptive immunotherapy  ... 
doi:10.1016/j.jtbi.2009.05.001 pmid:19446568 fatcat:niak7bxggvhllhyiu3y3sgebau
« Previous Showing results 1 — 15 out of 154,475 results